Charles River Laboratories Intl. Inc vs Lumen Technologies Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $227.69 (market cap $11.14B), while Lumen Technologies Inc trades at $6.45 (market cap $6.56B). The key difference: Charles River Laboratories Intl. Inc is the larger of the two by market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Lumen Technologies Inc nearer its low. Which is the better fit depends on your goals.
| CRL | LUMN | |
|---|---|---|
Market Cap | $11.14B | $6.56B |
Sector | Health | Media |
52-Week High | $233.60 | $11.83 |
52-Week Low | $145.57 | $3.70 |
Enterprise Value | $14.00B | $18.19B |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
LUMN trades at $6.45, down 4.16% today, reflecting ongoing investor caution amid a bearish technical signal. The company reported a net loss of $1.74 billion in 2025 despite beating earnings expectations in two of the last three quarters. Recent news highlights strategic moves like the Alkira acquisition to bolster its AI networking platform. Cash flow from operations remains strong at $4.74 billion, but high debt levels and negative profitability metrics pose challenges.
The outlook is mixed; cost-cutting and a $13 billion contract backlog offer potential upside, but persistent losses and a heavy debt load of $17.49 billion limit near-term growth. Analyst consensus is cautious with a hold-heavy rating, though the $8.25 price target implies modest upside from current levels if execution improves.
Trailing returns across standard periods
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →